GLP-1s are a breakthrough, but they are not the end of the story. To ensure lasting success, we must pair pharmacological interventions with behavioral support, personalized data, and continuous guidance.
Novo Nordisk, AbbVie, and Roche each have weekly injectable drug candidates designed to bind to and activate the amylin receptor to trigger weight loss. Metsera’s contender, MET-233i, is designed with technology that enables longer dosing intervals and the company is proceeding with development of this engineered peptide as a monotherapy and as part of a drug combination.
Explore top PTSD treatment centers in Arizona, offering personalized care, holistic therapies and expert support to help individuals heal and reclaim their lives.
Healthcare and benefits leaders must step up to provide menopausal women with the full-spectrum care they need to protect musculoskeletal and metabolic health for lifelong strength and well-being.
As healthcare costs continue to rise, three data-driven strategies can help companies reduce the expense of employee health benefits – without sacrificing quality.
GLP-1 medications are transforming how we think about chronic disease management and, more importantly, prevention. Ongoing research has found them to be effective in the prevention or treatment of diabetes, heart attacks and strokes, kidney disease, liver disease, sleep apnea, and more.
Pfizer said a patient dosed with danuglipron developed potential drug-induced liver injury. Pfizer is stopping further work on this program, a move that comes nearly two years after it discontinued development of a different obesity drug due to liver safety signals in a clinical trial.
A new report by Paubox calls for healthcare IT leaders to dispose of outdated assumptions about email security and address the challenges of evolving cybersecurity threats.
Engaging in data sharing, observational cohort research, and deeper analysis of available data to yield further insights can drive improved results for patients, making label and cohort extension faster and more robust.
CagriSema, a dual-acting drug in development by Novo Nordisk, met the goal of a Phase 3 test in patients with obesity and type 2 diabetes. But the topline results don’t show an advantage over Eli Lilly’s commercialized obesity medication, Zepbound.
For GLP-1 receptor agonists specifically, adherence challenges are a major concern, as these medications require long-term use to achieve meaningful health benefits in chronic conditions like diabetes and obesity.
Compounded GLP-1s have become more widespread, but are they safe? Some argue that compounding is nothing new, while others believe these drugs are dangerous for patients.
Healthcare is drowning in chaos—from scattered data to burnout-inducing tasks. Discover how smarter workflows and real-time insights can rescue care teams and transform patient outcomes.
Regulators will have their work cut out for them under a new administration that has expressed an anti-regulatory preference. Republicans next year will control the White House, Senate and House. What will it all mean for pharmacy leaders?
Investors showed appetite for Metsera’s IPO, as shares of the clinical-stage metabolic medicines biotech popped 47% in their Nasdaq debut. Maze Therapeutics and Beta Bionics also priced IPOs; the three companies raised $636 million combined.
Verdiva Bio’s once-a-week oral GLP-1 drug is ready for Phase 2 testing. The drug, made with a proprietary technology that enables oral dosing, was licensed from Sciwind Biosciences.
We must think beyond one-size-fits-all solutions and embrace the diversity of obstructive sleep apnea. This means continuing to innovate, collaborating across sectors, and keeping patients at the center of every decision.
Leaders from Red Cell Partners, an investment and incubation firm that funds and builds healthcare startups, shared key trends they’re keeping their eyes on this year — including increased adoption of AI agents and redefined GLP-1 management frameworks for employers.